

10/587184

Atty. Dkt. No. 052209-0150

AP20 Rev'd 10 25 JUL 2006

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Pierre J-M RIVIERE et al.
Title: TREATMENT OF BONE METASTASES BY MEANS
OF PTH RECEPTOR AGONISTS
Int'l. Appl. No.: PCT/US2005/001139
International Filing Date: 01/13/2005
Examiner: Unassigned
Art Unit: Unassigned
Confirmation Number: Unassigned

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §1.56

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Submitted herewith on Form PTO/SB/08 is a listing of documents known to Applicants in order to comply with Applicants' duty of disclosure pursuant to 37 CFR §1.56.

A copy of each non-U.S. patent document and each non-patent document is being submitted to comply with the provisions of 37 CFR §1.97 and §1.98.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

TIMING OF THE DISCLOSURE

The listed documents are being submitted in compliance with 37 CFR §1.97(b), within three (3) months of the filing date of the application.

RELEVANCE OF EACH DOCUMENT

All of the documents are in English.

Applicants respectfully request that each listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

Although Applicant believes that no fee is required for this Request, the Commissioner is hereby authorized to charge any additional fees which may be required for this Request to Deposit Account No. 19-0741.

Respectfully submitted,

Date July 25, 2006

By Courtenay C. Brinckerhoff

FOLEY & LARDNER LLP
Customer Number: 22428
Telephone: (202) 295-4094
Facsimile: (202) 672-5399

Courtenay C. Brinckerhoff
Attorney for Applicant
Registration No. 37,288

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT			Application Number	Unassigned	
			Filing Date	01/13/2005	
Date Submitted: July 25, 2006			First Named Inventor	Pierre J-M RIVIERE	
			Group Art Unit	Unassigned	
(use as many sheets as necessary)			Examiner Name	Unassigned	
			Attorney Docket Number	052209-0150	
Sheet	1	of	1		

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
	A1	WO	01/21 198	A1	ELI LILLY & COMPANY	3/29/2001		
	A2	WO	02/28420	A2	Michael F. HOLICK	4/11/2002		
	A3	WO	96/22790		XENOTECH INCORPORATED	8/1/1996		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A4	Eric A.G. BLOMME et al., "Skeletal Metastasis of Prostate Adenocarcinoma in Rats: Morphometric Analysis and Role of Parathyroid Hormone-Related Protein", The Prostate 39:187-197 (1999).	
	A5	M. KUBOTA et al., "Efficacy and specificity of human parathyroid hormone analogues as antagonists in intact clonal osteogenic sarcoma cells", Journal of Endocrinology (1986) 108, 261-265.	
	A6	Theresa A. GUISE et al., "Evidence for a Causal Role of Parathyroid Hormone - related Protein in the Pathogenesis of Human Breast Cancer - mediated Osteolysis", J. Clin. Invest., Vol. 98, No. 7, October 1996, pp. 1544-1549.	
	A7	Shafaat A. RABBANI et al., "OVER-PRODUCTION OF PARATHYROID HORMONE-RELATED PEPTIDE RESULTS IN INCREASED OSTEOLYTIC SKELETAL METASTASIS BY PROSTATE CANCER CELLS IN VIVO", Int. J. Cancer: 80, 257-264 (1999).	
	A8	Manali BENDRE MD et al., "Breast Cancer Metastasis to Bone It is Not all About PTHrP", CLINICAL ORTHOPAEDICS AND RELATED RESEARCH, Number 415S, pp. S39-S45 (2003).	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.